PL2238982T3 - Środek do terapii mięsaka tkanek miękkich - Google Patents

Środek do terapii mięsaka tkanek miękkich

Info

Publication number
PL2238982T3
PL2238982T3 PL10162953T PL10162953T PL2238982T3 PL 2238982 T3 PL2238982 T3 PL 2238982T3 PL 10162953 T PL10162953 T PL 10162953T PL 10162953 T PL10162953 T PL 10162953T PL 2238982 T3 PL2238982 T3 PL 2238982T3
Authority
PL
Poland
Prior art keywords
compound
formula
therapeutic agent
soft tissue
tissue sarcoma
Prior art date
Application number
PL10162953T
Other languages
English (en)
Inventor
Tatsuo Ito
Toshifumi Ozaki
Mamoru Ouchida
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of PL2238982T3 publication Critical patent/PL2238982T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PL10162953T 2003-06-27 2004-06-25 Środek do terapii mięsaka tkanek miękkich PL2238982T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2003183643 2003-06-27
EP04746840A EP1638541B1 (en) 2003-06-27 2004-06-25 Therapeutic agent for soft tissue sarcoma
EP10162953A EP2238982B8 (en) 2003-06-27 2004-06-25 Therapeutic agent for soft tissue sarcoma

Publications (1)

Publication Number Publication Date
PL2238982T3 true PL2238982T3 (pl) 2013-03-29

Family

ID=33549590

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10162953T PL2238982T3 (pl) 2003-06-27 2004-06-25 Środek do terapii mięsaka tkanek miękkich

Country Status (14)

Country Link
US (2) US7056883B2 (pl)
EP (2) EP1638541B1 (pl)
JP (1) JP4661782B2 (pl)
AT (1) ATE468113T1 (pl)
CA (1) CA2529840A1 (pl)
CY (1) CY1113534T1 (pl)
DE (1) DE602004027244D1 (pl)
DK (1) DK2238982T3 (pl)
ES (2) ES2341771T3 (pl)
MX (1) MXPA06000013A (pl)
PL (1) PL2238982T3 (pl)
PT (1) PT2238982E (pl)
SI (1) SI2238982T1 (pl)
WO (1) WO2005000332A2 (pl)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4238728B2 (ja) * 2001-08-21 2009-03-18 アステラス製薬株式会社 ヒストンデアセチラーゼ阻害剤の医薬用途ならびにその抗腫瘍効果の評価方法
US8673888B2 (en) * 2002-04-05 2014-03-18 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Depsipeptide for therapy of kidney cancer
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
EP1595952A4 (en) * 2003-02-19 2008-05-21 Astellas Pharma Inc METHOD FOR EVALUATING THE ANTITUMOR EFFECT OF A HISTONE DEACETYLASE INHIBITOR
US7381825B2 (en) 2003-03-17 2008-06-03 Takeda San Diego, Inc. Histone deacetylase inhibitors
ES2425083T3 (es) * 2003-09-25 2013-10-11 Astellas Pharma Inc. Agente antitumoral que comprende FK228 como inhibidor de histona desacetilasa y doxorrubicina como inhibidor de topoisomerasa II
US7951780B2 (en) * 2004-02-25 2011-05-31 Astellas Pharma Inc. Antitumor agent
US20060040575A1 (en) * 2004-08-18 2006-02-23 Kelleher Karen A Reflective printing on flame resistant fabrics
EP1824831A2 (en) 2004-12-16 2007-08-29 Takeda San Diego, Inc. Histone deacetylase inhibitors
EP1715334A1 (fr) * 2005-04-22 2006-10-25 Adamant Technologies SA Procédé utilisant un capteur électrochimique et électrodes formant ce capteur
NZ548087A (en) * 2005-04-29 2010-10-29 Tomizo Yamamoto Rubber or resin foam containing zirconium or germanium
EP1896436A2 (en) 2005-05-11 2008-03-12 Takeda San Diego, Inc. Histone deacetylase inhibitors
GB0511266D0 (en) * 2005-06-02 2005-07-13 Trust Chemical compounds
KR100809410B1 (ko) * 2005-07-06 2008-03-05 주식회사 브레인가드 줄기세포 분화 유도용 조성물 및 그의 용도
EA200800321A1 (ru) 2005-07-14 2008-06-30 Такеда Сан Диего, Инк. Ингибиторы гистондеацетилазы
EP1920779A4 (en) * 2005-08-12 2010-03-10 Astellas Pharma Inc YW753 PREPARATION STABILIZATION TECHNIQUE
AU2006283677A1 (en) * 2005-08-19 2007-03-01 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Topical formulations of histone deacetylase inhibitors and methods of using the same
GB0518720D0 (en) * 2005-09-14 2005-10-19 Hamlet Pharma Ab Therapeutic combination
CA2627129A1 (en) * 2005-11-04 2007-05-18 Merck & Co., Inc. Methods of using saha and bortezomib for treating cancer
JP2009514879A (ja) * 2005-11-04 2009-04-09 メルク エンド カムパニー インコーポレーテッド Ｓａｈａ、カルボプラチン及びパクリタキセルを用いて癌を治療する方法及びその他の併用療法
US20070197568A1 (en) * 2005-11-04 2007-08-23 Paul Bunn Methods of using SAHA and Erlotinib for treating cancer
US20070129290A1 (en) * 2005-11-18 2007-06-07 Or Yat S Metabolite derivatives of the HDAC inhibitor FK228
EP2012801A4 (en) * 2006-04-24 2009-08-05 Gloucester Pharmaceuticals Inc GEMCITABINE COMBINATION THERAPY
US8957027B2 (en) * 2006-06-08 2015-02-17 Celgene Corporation Deacetylase inhibitor therapy
CN101528037A (zh) * 2006-11-03 2009-09-09 默克公司 使用saha和硼替佐米治疗多发性骨髓瘤的方法
CN101687010A (zh) * 2006-12-29 2010-03-31 格洛斯特制药公司 制备Romidepsin
AU2007342028B2 (en) * 2006-12-29 2013-06-13 Celgene Corporation Purifiction of romidepsin
JP2010516767A (ja) * 2007-01-23 2010-05-20 グラスター ファーマシューティカルズ， インコーポレイテッド ロミデプシンおよびｉ．ａ．ボルテゾミブを含む併用療法
NZ605526A (en) 2010-07-12 2015-04-24 Celgene Corp Romidepsin solid forms and uses thereof
US8859502B2 (en) 2010-09-13 2014-10-14 Celgene Corporation Therapy for MLL-rearranged leukemia
CA2863291A1 (en) * 2012-01-12 2013-07-18 Celgene Corporation Romidepsin formulations and uses thereof
AU2013202506B2 (en) 2012-09-07 2015-06-18 Celgene Corporation Resistance biomarkers for hdac inhibitors
CA2887243C (en) 2012-10-15 2024-04-09 Epizyme, Inc. Methods of treating cancer
AU2013202507B9 (en) 2012-11-14 2015-08-13 Celgene Corporation Inhibition of drug resistant cancer cells
US9410943B2 (en) 2013-03-14 2016-08-09 The Board Of Trustees Of The Leland Stanford Junior University Methods, compositions and screens for therapeutics for the treatment of synovial sarcoma
EP3616754A1 (en) 2013-08-22 2020-03-04 Vanda Pharmaceuticals Inc. Cancer treatment
EP3057594A4 (en) * 2013-10-18 2017-06-07 Epizyme, Inc. Method of treating cancer
NZ630311A (en) 2013-12-27 2016-03-31 Celgene Corp Romidepsin formulations and uses thereof
MA40367A (fr) * 2014-07-03 2017-05-10 Imclone Llc Polythérapie
US10441644B2 (en) 2015-05-05 2019-10-15 The Regents Of The University Of California H3.3 CTL peptides and uses thereof
KR20180042356A (ko) 2015-08-24 2018-04-25 에피자임, 인코포레이티드 암 치료 방법
EP3746135A4 (en) 2018-01-30 2022-03-09 Foghorn Therapeutics Inc. METHODS AND COMPOUNDS FOR TREATMENT OF DISEASE
CN113874016A (zh) 2019-01-29 2021-12-31 福宏治疗公司 化合物及其用途
EP3917517A4 (en) 2019-01-29 2023-01-25 Foghorn Therapeutics Inc. CONNECTIONS AND USES THEREOF
US20230066136A1 (en) 2019-01-29 2023-03-02 Foghorn Therapeutics Inc. Compounds and uses thereof
US12384776B2 (en) 2019-01-29 2025-08-12 Foghorn Therapeutics Inc. Compounds and uses thereof
US20220154282A1 (en) * 2019-03-12 2022-05-19 The Broad Institute, Inc. Detection means, compositions and methods for modulating synovial sarcoma cells
WO2021022163A2 (en) 2019-07-31 2021-02-04 Foghorn Therapeutics Inc. Compounds and uses thereof
US12528825B2 (en) 2020-01-29 2026-01-20 Foghorn Therapeutics Inc. Compounds and uses thereof
EP4096651A4 (en) 2020-01-29 2024-01-24 Foghorn Therapeutics Inc. COMPOUNDS AND THEIR USES
US11787800B2 (en) 2020-07-29 2023-10-17 Foghorn Therapeutics Inc. BRD9 degraders and uses thereof
US11767330B2 (en) 2021-07-06 2023-09-26 Foghorn Therapeutics Inc. Citrate salt, pharmaceutical compositions, and methods of making and using the same

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60149520A (ja) * 1984-01-13 1985-08-07 Ajinomoto Co Inc 抗腫瘍剤
JPS61176523A (ja) 1985-01-30 1986-08-08 Teruhiko Beppu 制癌剤
GB8817743D0 (en) * 1988-07-26 1988-09-01 Fujisawa Pharmaceutical Co Fr901228 substance & preparation thereof
US5696273A (en) * 1991-02-28 1997-12-09 Parfums Christian Dior Method for synthesizing cucurbitine
US5700811A (en) * 1991-10-04 1997-12-23 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and method of use thereof
DE4137540A1 (de) * 1991-11-14 1993-05-19 Steigerwald Arzneimittelwerk Verwendung von praeparaten der curcuma-pflanzen
JP3399948B2 (ja) * 1992-06-26 2003-04-28 ザ トラスティーズ オブ プリンストン ユニバーシティ Ｐ９０抗体またはプローブを用いた前癌細胞または癌細胞の検出方法
US6124495A (en) * 1997-03-11 2000-09-26 Beacon Laboratories, Inc. Unsaturated oxyalkylene esters and uses thereof
IN188720B (pl) * 1997-11-06 2002-11-02 Panacea Biotec Ltd
AU2903300A (en) * 1999-03-03 2000-09-21 Ida Royalty Aps Novel pharmaceuticals, dietary supplements and cosmetic compositions, and the use of certain mixtures for preparing medicament or a dietary supplement for thetreatment or prevention of inflammation, hypersensitivity reactions or pain
CN1414971A (zh) 1999-12-08 2003-04-30 埃克斯西特治疗公司 用作免疫抑制剂的缩肽及其同类物
ATE425177T1 (de) * 2000-07-17 2009-03-15 Astellas Pharma Inc Reduziertes fk228 und seine verwendung
US6613534B2 (en) * 2001-03-20 2003-09-02 Wake Forest University Health Sciences MAP-2 as a determinant of metastatic potential
AR035455A1 (es) * 2001-04-23 2004-05-26 Hoffmann La Roche Derivados triciclicos de alquilhidroxamato , procesos para su elaboracion, composiciones farmaceuticas que los contienen, y el uso de dichos compuestos en la preparacion de medicamentos
US6905669B2 (en) 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
JP4238728B2 (ja) * 2001-08-21 2009-03-18 アステラス製薬株式会社 ヒストンデアセチラーゼ阻害剤の医薬用途ならびにその抗腫瘍効果の評価方法
AU2003226408B2 (en) * 2002-04-15 2007-06-14 Sloan-Kettering Institute For Cancer Research Combination therapy for the treatment of cancer
CA2433479A1 (en) * 2002-07-22 2004-01-22 F. Hoffmann-La Roche Ag Conjugate of a tissue non-specific alkaline phosphatase and dextran, process for its production and use thereof
CA2517346A1 (en) * 2003-02-27 2004-09-10 Leonard A. Cohen Treatment of canine hemangiosarcoma with a histone deacetylase inhibitor
US20050020557A1 (en) * 2003-05-30 2005-01-27 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with enzyme inhibitors

Also Published As

Publication number Publication date
EP1638541B1 (en) 2010-05-19
SI2238982T1 (sl) 2013-01-31
EP1638541A2 (en) 2006-03-29
JP2007521259A (ja) 2007-08-02
PT2238982E (pt) 2013-01-22
US20050107290A1 (en) 2005-05-19
US7056883B2 (en) 2006-06-06
JP4661782B2 (ja) 2011-03-30
CA2529840A1 (en) 2005-01-06
DE602004027244D1 (de) 2010-07-01
EP2238982B1 (en) 2012-10-17
EP2238982B8 (en) 2013-01-16
ES2341771T3 (es) 2010-06-28
ATE468113T1 (de) 2010-06-15
EP2238982A3 (en) 2011-03-02
WO2005000332A3 (en) 2005-03-24
WO2005000332A2 (en) 2005-01-06
DK2238982T3 (da) 2013-01-28
ES2397079T3 (es) 2013-03-04
US20060223747A1 (en) 2006-10-05
MXPA06000013A (es) 2006-03-21
EP2238982A2 (en) 2010-10-13
CY1113534T1 (el) 2016-06-22

Similar Documents

Publication Publication Date Title
EP2238982B8 (en) Therapeutic agent for soft tissue sarcoma
MY146111A (en) Acylaminopyrazoles as fgfr inhibitors
WO2005063745A8 (en) Novel spiroindoline or spiroisoquinoline compounds, methods of use and compositions thereof
DE60329001D1 (en) 8-hydroxychinolinderivate
AU2018256546A1 (en) Combination therapy with peptide epoxyketones
MY148688A (en) 2-methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mtor inhibitors
WO2008020027A3 (en) 2,5-dihydroxybenzene compounds for the treatment of skin cancer
WO2006067165A3 (en) Indolidone derivatives for the treatment or prevention of fibrotic diseases
MX2009006756A (es) Derivados de 1-amino-metil-l-fenil-ciclohexano como inhibidores de dpp-iv.
TW200728307A (en) Novel spirochromanone derivatives
IL189694A0 (en) Biphenyl derivatives and their use in treating hepatitis c
GEP20105134B (en) Agents for preventing and treating disorders involving modulation of the ryr receptors
UA96777C2 (ru) Фенилпропионамидные соединения и их применение как опиоидных агонистов
EP2639229A3 (en) Thiazole Derivative and use thereof as VAP-1 Inhibitor
ZA200600343B (en) Substituted 2-aminotetralin for the treatment of depression
WO2006113498A3 (en) 2-amino-quinaz0lin-5-ones as hsp90 inhibitors useful in treating proliferation diseases
MX2007013624A (es) Inhibidores de proteina cinasa.
UA96969C2 (en) Acylaminopyrazoles as fgfr inhibitors
UA96304C2 (en) 2-METHYLMORPHOLINE PYRIDO-, PYRAZO- AND PYRIMIDO-PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
WO2003074529A3 (en) iNDOLYL-UREA DERIVATIVES OF THIENOPYRIDINES USEFUL AS ANTI-ANGIOGENIC AGENTS
WO2008070010A3 (en) Hydroxylamine derivatives for the treatment of stroke
TW200639159A (en) Treatment of pain
EP2481429A3 (en) MMP Activated Vascular Disrupting Agents
WO2007047893A3 (en) Use of dasatinib for the treatment of bone metastasis
WO2006076569A3 (en) Bicyclic heterocycles as cannabinoid receptor modulators